Repare Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Repare Therapeutics Inc. reports its 2024 financial results and outlines a strategic shift to focus on RP-3467 and RP-1664, involving workforce reduction and seeking partnerships for other assets.
Repare Therapeutics Inc.'s 10-K filing details the termination of the Roche collaboration for camonsertib, the advancement of lunresertib and other pipeline programs, and the company's financial position.